GERMANTOWN, Md., Feb. 4, 2021 /PRNewswire/ -- Precigen,
Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing
in the development of innovative gene and cell therapies to improve
the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of
Precigen, will participate in a virtual fireside chat at the
Guggenheim Healthcare Talks Oncology Day on Friday, February 12, 2021 at 11:30 AM ET.
Participants may access the live webcast of the virtual event
through Precigen's website in the Events & Presentations
section at investors.precigen.com/events-presentations.
Precigen: Advancing Medicine with
Precision™
Precigen (Nasdaq: PGEN) is a
dedicated discovery and clinical stage biopharmaceutical company
advancing the next generation of gene and cell therapies using
precision technology to target the most urgent and intractable
diseases in our core therapeutic areas of immuno-oncology,
autoimmune disorders, and infectious diseases. Our technologies
enable us to find innovative solutions for affordable
biotherapeutics in a controlled manner. Precigen operates as an
innovation engine progressing a preclinical and clinical pipeline
of well-differentiated unique therapies toward clinical
proof-of-concept and commercialization. For more information about
Precigen, visit www.precigen.com or follow us on Twitter @Precigen
and LinkedIn.
Investor
Contact:
|
|
|
Media
Contact:
|
Steven
Harasym
|
|
|
Glenn
Silver
|
Vice President,
Investor
Relations
|
|
|
Lazar-FINN
Partners
|
Tel: +1 (301)
556-9850
|
|
|
glenn.silver@finnpartners.com
|
investors@precigen.com
|
|
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/precigen-to-participate-in-guggenheim-healthcare-talks-oncology-day-301222576.html
SOURCE Precigen, Inc.